EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH

View source ↗

Summary

Privigen (human normal immunoglobulin IVIg) has been authorised by the EMA for multiple indications. The listed therapeutic areas include idiopathic thrombocyto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Transplantation
• Guillain-barré Syndrome
• Idiopathic Thrombocytopenic Purpura
• Immunodeficiency Syndromes
• Kawasaki Disease

Drugs mentioned

• Privigen (intravenous immunoglobulin (IVIG))

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic;Bone Marrow Transplantation;Immunologic Deficiency Syndromes;Guillain-Barre Syndrome;Mucocutaneous Lymph Node Syndrome. MAH: CSL Behring GmbH. Decision date: 25/04/2025